The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2023Evaluating a Gene Therapy that Restores Mitochondrial Function as a Treatment for Parkinson’s Disease
Study Rationale: Currently, all treatments for Parkinson’s disease (PD) aim to improve symptoms by restoring or maintaining the levels of dopamine in the brain. No treatment on the market slows or...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program - Therapeutics, 2023Assessing the Ability of Dapansutrile, a Selective, Oral Inhibitor of the NLRP3 Neuroinflammatory Pathway, to Mitigate Progression of Parkinson’s Disease
Study Rationale: Increasing scientific data indicate the role of neuroinflammation in the pathology of Parkinson’s disease (PD) and related alpha-synucleinopathies. Dapansutrile (lab code: OLT1177®...
-
Novel PET Tracer Development Program, 2022Screening for PET Tracers that will Bind to the P2Y12 Receptor and Allow Monitoring of Microglia Activation During Neuroinflammation
Study Rationale: One of the hallmarks of Parkinson’s disease (PD) is neuroinflammation. During this dynamic process, the brain’s immune cells, called microglia, become activated and can either prolong...
-
Research Grant, 2023Mobility Matters: A Mobilise-D Extension Study
Study Rationale: Mobility, the ability to physically move around, is vitally important and key to an individual’s independence. Although loss of mobility is a key feature in Parkinson’s disease (PD)...
-
Improved Biomarkers and Clinical Outcome Measures, 2020Developing Assays to Quantify Cys106 of DJ-1 in Distinct Oxidized States as a Potential Diagnostic Tool for Parkinson’s Disease
Study Rationale:
Currently, there are no tools to predict whether someone is at risk of developing Parkinson’s disease or to diagnose the early stages of the disease before motor symptoms can be... -
Target Advancement Program, 2020Determining the Ligase and DUB Landscape of Mitochondrial and Alpha-synuclein Turnover
Study Rationale:
Research suggests that accumulation of faulty mitochondria (the “powerhouse” of the cell) or mutated forms of the protein alpha-synuclein in the brain contribute to the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.